Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 36

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 

Three Months EndedJune 30,Six Months EndedJune 30,(in millions, except per share data)2025202420252024Net sales$5,061 $4,120 $9,724 $7,977 Cost of products sold1,637 1,270 3,090 2,479 Gross profit3,424 2,850 6,633 5,498 Operating expenses:Selling, general and administrative expenses1,716 1,446 3,312 2,810 Research and development expenses526 383 969 749 Royalty expense14 9 28 19 Amortization expense225 213 444 427 Intangible asset impairment charges46 276 46 276 Contingent consideration net expense (benefit)(5)2 0 18 Restructuring net charges (credits)83 1 93 5  2,605 2,330 4,894 4,303 Operating income (loss)819 520 1,740 1,195 Other income (expense):Interest expense(90)(77)(172)(146)Other, net213 (23)179 (21)Income (loss) before income taxes941 420 1,746 1,028 Income tax expense (benefit)146 98 279 213 Net income (loss)795 322 1,467 815 Net income (loss) attributable to noncontrolling interests(2)(2)(4)(4)Net income (loss) attributable to Boston Scientific common stockholders$797 $324 $1,471 $819 Net income (loss) per common share — basic$0.54 $0.22 $0.99 $0.56 Net income (loss) per common share — diluted$0.53 $0.22 $0.98 $0.55 Weighted-average shares outstandingBasic1,479.9 1,470.6 1,478.5 1,469.5 Diluted1,493.5 1,484.2 1,493.3 1,483